This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2022 Sep 8;45(9):zsac138.

doi: 10.1093/sleep/zsac138.

Deprescribing antihypertensive drugs after starting OSA primary therapy: "first do no net harm?"

Andrea Romigi¹

Affiliations

PMID: 35802048
DOI: 10.1093/sleep/zsac138

Comment

Deprescribing antihypertensive drugs after starting OSA primary therapy: "first do no net harm?"

Andrea Romigi. Sleep. 2022.

. 2022 Sep 8;45(9):zsac138.

doi: 10.1093/sleep/zsac138.

Author

Andrea Romigi¹

Affiliation

¹ Sleep Medicine Center IRCCS Neuromed, Pozzilli (IS), Italy.

PMID: 35802048
DOI: 10.1093/sleep/zsac138

No abstract available

PubMed Disclaimer

Comment in

Impact of OSA primary therapy on antihypertensive drugs use.
Revol B, Castelli C, Joyeux-Faure M, Pépin JL. Revol B, et al. Sleep. 2022 Sep 8;45(9):zsac151. doi: 10.1093/sleep/zsac151. Sleep. 2022. PMID: 35802044 No abstract available.

Comment on

Deprescribing antihypertensive drugs after starting OSA primary therapy?
Revol B, Castelli C, Ben Messaoud R, Coffy A, Bailly S, Jullian-Desayes I, Martinot JB, Martinot P, Joyeux-Faure M, Pépin JL. Revol B, et al. Sleep. 2022 May 12;45(5):zsac060. doi: 10.1093/sleep/zsac060. Epub 2022 Mar 25. Sleep. 2022. PMID: 35554591 No abstract available.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems